Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
Year: 2016
Type: review
Abstract: The emergence of immune 'checkpoint inhibitors' such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1) has revolutionized treatment of solid tumors including melanoma, lung cancer, among many others. The goal of checkpoint inhibitor combination therapy is to improve clinical response and minimize toxicities. Rational design of checkpoint combinations considers immune-mediated mechanisms of antitumor activity: immunogenic cell death, antigen release and presentation, activation of T-cell responses, lymphocytic infiltration into tumors and depletion of immunosuppression. Potential synergistic combinations include checkpoint blockade with conventional (radiation, chemotherapy and targeted therapies) and newer immunotherapies (cancer vaccines, oncolytic viruses, among others). Reliable biomarkers are necessary to define patients who will achieve best clinical benefit with minimal toxicity in combination therapy.
Source: Immunotherapy
Authors: Chrisann Kyi, Michael A Postow
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: immune checkpoint inhibitors, CTLA-4, PD-1, combination therapy, solid tumors, immunogenic cell death, antigen presentation, T cell activation, tumor immune infiltration, immunosuppression, radiotherapy, chemotherapy, targeted therapy, cancer vaccines, oncolytic viruses, biomarkers, toxicity
Open Access status: green
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W2466182055
